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ABSTRACT
Background: The insertion of urinary catheters during urinary surgical inter-
entions may lead to catheter-related bladder discomfort (CRBD) in the postoperative period.
Objective: We aimed to evaluate the effect of single-dose intravenous parac-
etamol on CRBD.
Methods: In this randomized, controlled, double-blind study, 64 patients (age
18 years, American Society of Anesthesiologists Physical Status I–II) requiring
urinary bladder catheterization for percutaneous nephrolithotomy were assigned to
groups that received either intravenous paracetamol (15 mg/kg) (group P) or NaCl
0.9% solution (control group [group C]) 30 minutes before the end of surgery.
Patients received patient-controlled analgesia (10-mg bolus of meperidine, without
infusion, 20-minute lock out) postoperatively. CRBD and pain status were assessed at
30 minutes and 1, 2, 4, 6, and 12 hours postoperatively. Postoperative meperidine
requirement and patient and surgeon satisfaction were assessed.
Results: Group P had significantly lower CRBD scores at all time points
except at 12 hours postoperatively compared with group C (P  0.05). Total
meperidine consumption was significantly higher in group C (P 0.05). Patient and
surgeon satisfaction scores were significantly higher in group P (P  0.05).
Conclusions: Intraoperative single-dose paracetamol was found to be effec-
tive in reducing the severity of CRBD and pain in urologic surgery. We suggest that
it may be an efficient, reliable, easy-to-apply drug for CRBD. ClinicalTrials.gov
identifier: NCT01652183. (Curr Ther Res Clin Exp. 2012;73:186–194) © 2012
Elsevier HS Journals, Inc.Elsevier HS Journals, Inc. All rights reserved.
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P. Ergenoglu et al.INTRODUCTION
The insertion of an urinary catheter in a patient undergoing a surgical procedure,
especially urinary interventions, may lead to catheter-related bladder discomfort
(CRBD) with varying degrees of severity during the postoperative period. CRBD
symptoms associated with an indwelling urinary catheter are similar to overactive
bladder (OAB) symptoms such as discomfort in the suprapubic region, urinary
urgency, frequency, and a burning sensation with or without urge incontinence.1,2
The clinical appearance of CRBD and OAB are both associated with involuntary
etrusor smooth muscle contractions, in which prostaglandins (PGs) have been
eported to be responsible for low urinary tract function leading to micturition reflex
y triggering bladder contraction.3 The previous studies reported the incidence of
CRBD as ranging from 50% to 90%.2,4–6 The high incidence of patient discomfort
ay result in a prolonged hospital stay in the postoperative care unit. For this reason,
he anesthesiologists should be aware of the symptoms of CRBD.
The goal of the various treatment options for CRBD has been to control invol-
ntary urinary bladder contractions.4 However, these therapies may also induce
ndesirable effects such as restlessness, agitation, and inadequate response to pain
reatment, particularly in the early postoperative period.
Paracetamol is a drug with proven efficacy for the management of mild and
oderate postoperative pain.7 It inhibits PG synthesis.8 Based on the same mecha-
nism, the inhibiting effects of paracetamol on PG synthesis may also alleviate the
symptoms of CRBD. To our knowledge, this is the first study is to evaluate the effect
of intravenous paracetamol on CRBD. In this study, according to this common
pathway, we aimed to address the effect of single-dose intravenous paracetamol on
CRBD after percutaneous nephrolithotomy (PNL).
PATIENTS AND METHODS
After obtaining approval from the University Research Ethics Committee (Baskent
University Research Ethics Committee, Ankara, Turkey, KA08/180) and written in-
formed consent from the patients, 64 patients were included in this double-blind,
randomized, controlled study. The study was completed in 12 months. The inclusion
criteria were 18 years of age, American Society of Anesthesiologists Physical Status of
I to II, undergoing PNL with a urinary bladder catheter. The exclusion criteria were
obesity (body mass index 30), long-term opioid use, bladder outflow obstruction,
benign prostatic hyperplasia, and OAB (frequency3 times at night or8 times within
4 hours). We used a computer-generated randomized number list for sealed envelopes.
hese envelopes were prepared by a nurse who was not associated with the study. The
nvelopes were opened by the anesthesia technician who prepared the study drugs.
The patients were randomly divided into 2 groups: group P (paracetamol group,
 32) received 15 mg/kg paracetamol intravenously and group C (control group,
 32) received 1.5 mL/kg 0.9% NaCl solution intravenously 30 minutes before the
nd of surgery. The study drugs were prepared, labeled, and covered with opaque
aper in a drug preparation room and brought to operating theater before anesthesia
nduction by an anesthesiologist who was not part of the study. The anesthesiologist
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group allocation throughout the entire study period, including the first 24 hours
postoperatively. All postoperative assessments and data recording were performed by
an anesthesiologist blinded to patient allocation and study drugs.
A peripheral intravenous line was placed using an 18- or 20-gauge catheter in
patients. No premedication was administered. Routine anesthesia monitoring was
performed using 5-lead electrocardiography, noninvasive blood pressure measure-
ment, and pulse oximetry. Anesthesia was induced with intravenous 3 to 5 mg/kg
thiopental sodium and 1 g/kg fentanyl, and endotracheal intubation was facilitated
with vecuronium bromide 0.1 mg/kg. Anesthesia was maintained with mixture of
isoflurane 1% to 2% and N2O/O2 (FiO2, 50%). Additional muscle relaxants were
administered when needed.
After induction of anesthesia, urinary catheterization was performed using an
18-French urinary catheter with patients in the lithotomy position; the catheter
balloon was inflated with 10 mL of 0.9% NaCl. At the end of the surgery, all patients
had a nephrostomy catheter, and infiltration of the insertion site with 20 mL 0.25%
bupivacaine for postoperative analgesia was performed. Thirty minutes before the end
of surgery, paracetamol 15 mg/kg was administered to group P, whereas the same
volume of saline solution was delivered in group C. The neuromuscular block was
reversed by neostigmine 0.05 mg/kg and atropine 0.015 mg/kg for extubation, and
the patients were transferred to the recovery room.
Each patient received patient-controlled intravenous analgesia with meperidine
(10-mg bolus, 20-minute lock out, no infusion dose, and 4-hour limit) for postop-
erative analgesia. All patients were to receive tenoxicam 20 mg intravenously as
rescue analgesia when the visual analog scale (VAS) score was 3.
Each patient’s age, sex, duration of surgery, kidney stone size, and nephrostomy
tube size were recorded. CRBD was evaluated with a 4-point scale (1  no discom-
ort; 2  mild, revealed on questioning only; 3  moderate, stated by the patient
ithout being questioned; 4  severe, urinary urgency demonstrated by behavioral
esponses such as attempts to remove the urinary catheter, restless extremity move-
ents, verbal responses) 30 minutes and 1, 2, 4, 6, and 12 hours postoperatively.
Postoperative pain levels due to percutaneous tract and nephrostomy catheter were
valuated by the VAS score (0  no pain, 10  worst pain possible). Although pain
anagement was aimed to be kept to VAS scores of 3, the analgesia level and total
mount of delivered meperidine were recorded postoperatively at the same time points.
Sedation levels were assessed according to Ramsey Sedation Scale (1  anxious and
gitated, 2 cooperative and calm; 3 drowsy but responsive to commands, 4 asleep
ut responsive to a glabellar tap, 5  asleep with a sluggish response to tactile stimu-
ation, 6  asleep and no response), heart rate (HR), systolic blood pressure (SBP),
iastolic blood pressure (DBP), and peripheral oxygen saturation (SpO2) were assessed
postoperatively at the same time points. Postoperative potential adverse effects such
as bradycardia (HR 60/min), hypotension (SBP 90 mm Hg), respiratory depres-
sion (SpO290%), nausea, vomiting, and deep sedation were carefully monitored and
ecorded during the 24-hour postoperative period.
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P. Ergenoglu et al.Patient and surgeon satisfaction was also assessed with a 4-point Likert scale (1 
very satisfied, 2  somewhat satisfied, 3  somewhat dissatisfied, 4  very dissat-
isfied) at 24 hours after the surgery.
Sample size calculation was based on the initial pilot study. First, we started the
study with 12 patients in each group who were not included in the study. The power was
80% in the sample size calculation. Using the data acquired from those patients, we
observed a mean standardized effect of 0.5 and a mean correlation of 0.35 for the
lower triangle of correlations obtained from repeated CRBD severity scores. According to
an article by Rochon9, we decided that 64 patients were required for the study.
Data analysis was performed using SPSS 18.0 (version 11.0, SPSS Inc, Chicago,
Illinois). Categorical variables were expressed as numbers and percentages, whereas
numerical variables were expressed as means (SDs) or as median and minimum-
maximum values in come cases. The intergroup comparison of categorical variables
was performed using the 2 test. The intergroup comparison of numerical variables
as performed using a t test when the assumptions were fulfilled and the Mann-
hitney U test when the assumptions were not fulfilled. A repeated-measures
NOVA was used to compare the variances occurring over time in the same
ndividuals. P  0.05 was recognized as statistically significant.
RESULTS
Sixty-four patients scheduled for PNL were enrolled in the study. Figure 1
presents the allocation of patients in groups. The groups were comparable with
respect to demographic data, nephrostomy tube size, duration of surgery, and
stone size (Table I).
The CRBD scores showed significant differences between the groups at all time
points except the values at 12 hours (Figure 2). The number of patients who
experienced moderate discomfort was significantly lower in group P compared
with group C at 1, 2, 4, and 6 hours (P  0.05). None of the patients in group
P had severe CRBD at all time points except 1 patient at the 1 hour postoper-
atively (Table II).
Comparison of VAS scores showed that the scores were lower in group P than in
group C when measurements were performed within the first 2 hours postoperatively.
However, the difference between the groups was not statistically significant, and the
following measurements revealed only minimal differences between the 2 groups in
terms of VAS scores (P  0.05) (Table III). Total consumption of meperidine was
ignificantly higher in group C (group P: 52.72 [63.73] mg; group C: 75.81 [58.16]
g; P  0.018), and no patients required rescue analgesia with tenoxicam.
Regarding the Ramsey Sedation Scale, the number of agitated and anxious patients
as significantly higher in group C at 30 minutes and 1 hour (P  0.001 and P 
.04, respectively); however, all patients were observed to be calm and cooperative
fter 2 hours.
There were no significant intergroup or intragroup differences regarding HR, SBP,
nd DBP. None of the patients exhibited hypotension, hypertension, bradycardia,
achycardia, or excessive sedation. Patient satisfaction scores were 4.53 (0.51) in group
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Current Therapeutic ResearchP and 3.84 (0.95) in group C. The results for patient satisfaction were significantly higher
in group P (P 0.002). Surgeon satisfaction scores were also significantly higher in group
P (group P: 4.75 [0.44]; group C: 4.03 [0.82]; P  0.001).
Initial pilot study (n = 12)
Assessed for eligibility (n = 64)
Randomized (n = 64)
Allocation
Enrollment
Follow-up
Analysis
Excluded (n = 0)
Allocated to control group (n = 32)
Analyzed (n = 32)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
• Not meeting inclusion criteria (n = 0)
• Declined to participate (n = 0)
• Other reasons (n = 0)
• Received allocated intervention (n = 32)
• Did not receive allocated intervention (n = 0)
Allocated to paracetamol group (n = 32)
• Received allocated intervention (n = 32)
• Did not receive allocated intervention (n = 0)
•Excluded from analysis (n = 0)
Analyzed (n = 32)
•Excluded from analysis (n = 0)
Figure 1. Study flow chart.
Table I. Demographic and surgical characteristics.
Group P, Mean (SD) Group C, Mean (SD)
ge, y 40.50 (12.72) 43.88 (12.75)
eight, m 168.03 (5.96) 166.19 (6.46)
eight, kg 71.97 (12.42) 71.16 (10.53)
uration of surgery, min 61.88 (31.82) 56.41 (25.44)
Renal stone size, cm2 7.88 (4.12) 7.34 (3.98)
Nephrostomy catheter size, French 18.69 (0.97) 18.81 (1.00)Data expressed as mean (SD).
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In this study, we evaluated the efficacy of paracetamol in patients who underwent
PNL and urinary catheterization with regard to the clinical mechanisms of CRBD.
We found that an intraoperative single dose of intravenous paracetamol decreases the
severity of CRBD and meperidine consumption.
Urinary catheters inserted in the bladder for urologic surgeries may become a serious
source of discomfort for patients. CRBD is an important entity that should be monitored
to ensure patient satisfaction. Anesthesiologists must alleviate the stressful CRBD symp-
toms during the postoperative period to avoid a high incidence of CRBD. The clinical
profile of CRBD, characterized by frequent and urgent need for urination, is very similar
to that of OAB, which is characterized by urinary urgency with or without urge
incontinence. Therefore, medications effective in treating OAB were also investigated in
the management of CRBD.2,4,6 Oxybutynin, an inhibitor of acetylcholine in smooth
Table II. Number of patients with catheter-related bladder discomfort.
Discomfort
Time
30 min 1 h 2 h 4 h 6 h 12 h
P C P C P C P C P C P C
one, no. 10 4 12 5 13 7 20 7 23 10 24 22
ild, no. 13 8 12 7 16 8 9 7 9 10 7 10
oderate, no. 9 13 7* 14 3† 14 1‡ 18 0‡ 12 1 0
Severe, no. 0§ 7 1* 6 0 3 0 0 0 0 0 0
C  control group (n  32); P  paracetamol group (n  32).
*P  0.018.
†P  0.002.
‡P  0.001.
4
3
2
1
0
30 min
* * ‡
‡
†
1 h 2 h 4 h 6 h 12 h
Group C
Group P
Figure 2. Severity of catheter-related bladder discomfort. Group C, control group; Group P,
paracetamol group. *P  0.002; †P  0.001; ‡P < 0.001.§P  0.009.
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Current Therapeutic Researchmuscles, and tolterodine, a competitive muscarinic acid, both of which are also used in
OAB treatment, have been reported to achieve successful outcomes in relieving CRBD
symptoms. However, these agents may initiate undesirable effects such as dry mouth,
facial blushing, and blurry vision. Moreover, they are known to make no contribution to
postoperative analgesia.4,10 Gabapentin, an anticonvulsant drug, has also been studied in
he treatment of CRBD symptoms because of its inhibitor activity on afferent C fibers by
uppressing peripheral sensitization, which is similar to OAB.6,11 However, the use of
abapentin for urologic dysfunction has been an off-label use and has no positive impact
n postoperative pain. Ketamine, which binds with N-methyl-D-aspartate, muscarinic,
and cholinergic receptors, has been shown to reduce the severity and incidence of CRBD.
However, intravenous ketamine has been found to be associated with increased level of
sedation despite the use of subhypnotic doses.5
Elevated urinary levels of PGE2 in patients with OAB and lower urinary tract
obstruction suggest that PGE2 may play a role in these clinical entities.
12–14 PGs are
roduced in detrusor muscles and mucosa and play an important role in the regulation of
ower urinary tract functions.15 PG synthesis has been shown to be triggered by physi-
ologic stimulations such as detrusor muscle contraction, damage in the bladder mucosa,
nerve excitation, and activity of inflammation mediators such as bradykinin.16 The
mechanism of elevated PG synthesis during CRBD may be the increased activation of
cyclooxygenase-2 (COX-2) enzyme, the inducible group of COX enzymes, with inflam-
matory stimulation due to the presence of the catheter. Thus, an elevated PGE2 level may
lead to the occurrence of CRBD with lower urinary tract symptoms such as urinary
urgency, frequent urination, and urge incontinence.
Regarding the possible mechanism of CRBD, we hypothesized the use of paracetamol,
which has been shown to inhibit PG synthesis in intact cells and act as a COX-2 inhibitor,
would alleviate the occurrence and symptoms of CRBD.17,18 Paracetamol has been
commonly preferred for the management of postoperative pain and has the advantage of
causing fewer adverse effects than nonsteroidal anti-inflammatory drugs and opioids.19
Paracetamol has also been shown to significantly inhibit PGE2 release from the dorsal
orn of the spinal cord in rats.20 Moreover, paracetamol has been shown to selectively
Table III. VAS values of the groups.
VAS
Score
Group P: Mean (SD),
Median (Min-Max)
Group C: Mean (SD),
Median (Min-Max) P
30 min 2.19 (1.49), 3 (0–4) 2.94 (0.88), 3 (0–4) 0.055
h 1.84 (1.25), 2 (0–3) 2.41 (0.84), 2.5 (0–4) 0.119
h 2.06 (1.11), 2 (0–3) 2.19 (1.0), 2.5 (0–3) 0.609
h 1.97 (1.15), 2 (0–3) 2.09 (1.03), 2 (0–3) 0.783
h 1.88 (1.26), 2 (0–3) 1.91 (0.93), 2 (0–3) 0.520
2 h 1.63 (1.26), 2 (0–3) 1.53 (1.02), 2 (0–3) 0.453
Group C  control group; Group P  paracetamol group; Min-Max  minimum-maximum; VAS  visual
nalog scale.uppress peripheral PGE2 release in patients with acute inflammation after a brief surgical
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advantage during intraoperative general anesthesia practice.
In this study, CRBD was significantly less in patients who received paracetamol
intraoperatively during PNL. This may be attributed to the assumption that intraoper-
ative paracetamol delivery may have a therapeutic impact on CRBD. Pain scores were
comparable in both groups; however, meperidine consumption was significantly higher in
group C. This result may be interpreted as CRBD symptoms possibly aggravating the
pain during the postoperative period.22 However, the 23-mg difference in meperidine
consumption between groups might be important for clinical management of patients
with specific physical characteristics and postoperative needs for pain relief in clinics.
The patients in group P were less agitated and anxious in the early postoperative
period. When compared with the other agents, also having sedative properties, used
for CRBD treatment, the adequate level of recovery may be regarded as an advantage
of intravenous paracetamol. Furthermore, patient and surgeon satisfaction assessments
also favor paracetamol use for the management of CRBD.
The main limitation of this study was the possibility of misperception between
CRBD and surgical symptoms such as pain and abdominal discomfort. In other
words, surgery-related discomfort may blunt the accuracy of CRBD assessment. We
believe that local anesthetic infiltration to the surgical site and effective postoperative
pain management may relieve concerns about this issue.
In conclusion, we suggest that paracetamol is an effective drug in the management
of CRBD.
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